Fig. 2

Tumour immune microenvironments according to different clinical settings. TKI, tyrosine kinase inhibitor, IM-PD, imatinib-progressed and no exposure to sunitinib or regorafenib, IM-PD/SU-treated, imatinib-progressed and sunitinib and/or regorafenib-treated a CD3⁺ per total DOG-1⁺; b CD8⁺ CD3⁺ per total CD3⁺; c Ki-67⁺ CD3⁺ per total CD3⁺; d Ki-67⁺ DOG-1⁺ per total DOG-1⁺; e FoxP3⁺ CD3⁺ per total CD3⁺; f CD204⁻ CD68⁺ per total DOG-1⁺; g CD204⁺ CD68⁺ per total DOG-1⁺